|
|
Vaccine Detail
|
HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine |
| Vaccine Information |
- Vaccine Name: HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: HER-2-neu and carcinoembryonic antigen synthetic peptides (NCT00091286; NCIT_C48392)
- Immunization Route: Other
- Description: This is a vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic activity. The vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. (NCIT_C48392) Vaccines made from peptides may make the body build an immune response to kill tumor cells. This vaccine is compromised of HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51, and aims to cause an immune response in patients with stage IIB, III, or IV colorectal cancer. (NCT00091286)
|
| Host Response |
|
|
| References |
NCIT_C48392: HER-2-neu, CEA Peptides, GM-CSF, Montanide ISA-51 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48392]
NCT00091286: Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer [https://clinicaltrials.gov/study/NCT00091286]
|
|
